Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer.

[1]  O. De Wever,et al.  Fibroblasts Fuel Immune Escape in the Tumor Microenvironment. , 2019, Trends in cancer.

[2]  K. Shim,et al.  Diffuse splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer , 2019, Scientific Reports.

[3]  B. Lindsey,et al.  Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1 , 2018, Sarcoma.

[4]  Ji-In Bang,et al.  Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer , 2018, PloS one.

[5]  M. Mauro,et al.  The Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis , 2018, Blood.

[6]  W. De Neve,et al.  Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates , 2018, BMC Cancer.

[7]  C. Houser,et al.  Use of Functional Magnetic Resonance Imaging in Cervical Cancer Patients With Incomplete Response on Positron Emission Tomography/Computed Tomography After Image-Based High-Dose-Rate Brachytherapy. , 2018, International journal of radiation oncology, biology, physics.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  C. Moon,et al.  Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer , 2018, PloS one.

[10]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[11]  S. Fanti,et al.  Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer , 2018, International Journal of Gynecologic Cancer.

[12]  Jieying Zhang,et al.  Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT , 2018, Theranostics.

[13]  Steve Y. Cho,et al.  Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? , 2018, Nuclear Medicine and Molecular Imaging.

[14]  F. Landoni,et al.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  G. Roman-Jimenez,et al.  Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Jae Kwan Lee,et al.  Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer , 2016, Nuclear medicine communications.

[17]  D. Milne,et al.  Spleen to liver ratio (SLR): Novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. , 2016 .

[18]  John O. Prior,et al.  [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy , 2016, Radiation Oncology.

[19]  P. Høilund-Carlsen,et al.  FDG PET/CT in cancer: comparison of actual use with literature-based recommendations , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  J. Min,et al.  Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. , 2015, JACC. Cardiovascular imaging.

[21]  J. Java,et al.  Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. , 2014, Gynecologic oncology.

[22]  Dong Soo Lee,et al.  Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis , 2014, The Journal of Nuclear Medicine.

[23]  H. Kim,et al.  Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma , 2013, Nuklearmedizin.

[24]  M. Pittet,et al.  The spleen in local and systemic regulation of immunity. , 2013, Immunity.

[25]  L. Delrue,et al.  Completion Surgery After Intensity-Modulated Arc Therapy in the Treatment of Locally Advanced Cervical Cancer: Feasibility, Surgical Outcome, and Oncologic Results , 2013, International Journal of Gynecologic Cancer.

[26]  Kyoungjune Pak,et al.  Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography , 2013, Nuclear medicine communications.

[27]  P. Grigsby,et al.  FDG-PET-based prognostic nomograms for locally advanced cervical cancer. , 2012, Gynecologic oncology.

[28]  C Marini,et al.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  J. Ochando,et al.  Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. , 2012, Cell reports.

[30]  H. Chung,et al.  Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. , 2011, Gynecologic oncology.

[31]  Wolfgang A Weber,et al.  Quantitative analysis of PET studies. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  T. Yen,et al.  Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. , 2009, International journal of radiation oncology, biology, physics.

[33]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Grigsby,et al.  The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival , 2007, Cancer.

[35]  P. Grigsby,et al.  F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. , 2006, Gynecologic oncology.

[36]  P. Grigsby,et al.  Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[37]  Y Narita,et al.  Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. , 1999, International journal of radiation oncology, biology, physics.

[38]  G. Thomas.  Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. , 1999, The New England journal of medicine.

[39]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[40]  L. Azoulay,et al.  Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. , 2011, AJR. American journal of roentgenology.